SGP — Spyglass Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $750.76m
- $643.32m
Annual cashflow statement for Spyglass Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -13.3 | -29.2 | -39.9 |
| Depreciation | |||
| Non-Cash Items | 0.989 | 5.31 | 4.18 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -0.071 | 1.55 | 2.37 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -24.6 | -44.1 | -65.4 |
| Capital Expenditures | -0.217 | -1.99 | -0.789 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -20.3 | 24.3 | -11 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -41 | 44.5 | -23.6 |
| Financing Cash Flow Items | — | — | -1.18 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 79.5 | 0.37 | 249 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 7.01 | 0.419 | 80.1 |